A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
M AuerbachG Briefel

Abstract

Forty-three hemodialysis patients receiving recombinant erythropoietin (rHuEPO, epoietin alpha) were randomized to receive intravenous iron dextran as a total-dose infusion, 500-mg infusion to total dose, or 100-mg bolus to total dose, in each case during the dialysis procedure. The dose of iron dextran was calculated from the patient's existing hemoglobin to achieve a desired hemoglobin. Patients were eligible to receive intravenous iron dextran if they had a serum ferritin of < or = 100 ng/mL or a serum ferritin of 100 to 200 ng/mL, along with a transferrin saturation of < or = 19%. Patients were excluded if they had prior therapy with iron dextran, aluminum intoxication, or transfusion during the study. The time to the maximum hemoglobin, acute adverse reactions, and delayed adverse reactions were analyzed statistically, and no differences were seen in any of the three groups. Total-dose intravenous iron dextran infusion is safe, convenient, less expensive, and as efficacious as divided-dose infusions.

Citations

Oct 20, 2010·QJM : Monthly Journal of the Association of Physicians·S SinhaP A Kalra
Jan 18, 2011·Hematology·Michael Auerbach, Harold Ballard
May 26, 2012·ClinicoEconomics and Outcomes Research : CEOR·Vassilis FragoulakisNikolaos Maniadakis
Apr 18, 2013·Best Practice & Research. Clinical Anaesthesiology·Michael AuerbachAryeh Shander
Jul 22, 2008·Annals of Hematology·Nils Milman
Sep 27, 2015·American Journal of Hematology·Michael Auerbach, John W Adamson
Mar 20, 1999·Kidney International. Supplement·S FishbaneJ K Maesaka
Jun 21, 2011·Néphrologie & thérapeutique·Patrick FievetRenato Demontis
Dec 28, 2010·Néphrologie & thérapeutique·Patrick Fievet, François Brazier
Jan 6, 2000·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·G R BailieN A Mason
Mar 10, 1999·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·G R Matzke
May 8, 2007·Lancet·Michael AuerbachJohn Glaspy
Dec 19, 2007·Journal of Interventional Cardiology·Ron WaksmanFermin O Tio
Nov 17, 2007·International Journal of Clinical Practice·C M ReddyM Walsh
Feb 15, 2008·American Journal of Hematology·Michael AuerbachHarold Ballard
Jan 10, 2014·Current Opinion in Nephrology and Hypertension·Derek S Larson, Daniel W Coyne
Dec 30, 2014·Journal of the American Society of Nephrology : JASN·David M CharytanUNKNOWN Dialysis Advisory Group of the American Society of Nephrology
Jul 6, 2013·American Journal of Hematology·Michael AuerbachHuzefa Bahrain
Dec 29, 2000·Current Opinion in Nephrology and Hypertension·R van Zyl-Smit
Mar 16, 2000·Renal Failure·D BhowmikS C Dash
Dec 24, 2020·Internal Medicine Journal·Syarihan KarimMurray L Barclay
Dec 1, 2001·Clinical Therapeutics·J Q Hudson, T J Comstock
Mar 7, 2000·Journal of the American Society of Nephrology : JASN·Anatole BesarabAjay Gupta
Sep 7, 1999·Journal of the American Society of Nephrology : JASN·A BesarabJ Yee
Jul 13, 1999·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·N Mittman
Mar 7, 2001·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.